Post-COVID syndrome: an insight on its pathogenesis
Post-COVID syndrome is increasingly recognized as a new clinical entity in the context of
SARS-CoV-2 infection. Symptoms persisting for more than three weeks after the diagnosis of …
SARS-CoV-2 infection. Symptoms persisting for more than three weeks after the diagnosis of …
[HTML][HTML] Fluvoxamine: a review of its mechanism of action and its role in COVID-19
Fluvoxamine is a well-tolerated, widely available, inexpensive selective serotonin reuptake
inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized …
inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized …
Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia
A Greinacher, K Selleng, R Palankar… - Blood, The Journal …, 2021 - ashpublications.org
Abstract SARS-CoV-2 vaccine ChAdOx1 nCoV-19 (AstraZeneca) causes a thromboembolic
complication termed vaccine-induced immune thrombotic thrombocytopenia (VITT). Using …
complication termed vaccine-induced immune thrombotic thrombocytopenia (VITT). Using …
SARS-CoV-2 vaccine–induced immune thrombotic thrombocytopenia
DB Cines, JB Bussel - New England Journal of Medicine, 2021 - Mass Medical Soc
The coronavirus disease 2019 (Covid-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) stimulated the development of highly effective …
syndrome coronavirus 2 (SARS-CoV-2) stimulated the development of highly effective …
Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection
Herein, we consider venous immunothrombotic mechanisms in SARS-CoV-2 infection and
anti-SARS-CoV-2 DNA vaccination. Primary SARS-CoV-2 infection with systemic viral RNA …
anti-SARS-CoV-2 DNA vaccination. Primary SARS-CoV-2 infection with systemic viral RNA …
COVID‐19 Vaccine‐associated Immune Thrombosis and Thrombocytopenia (VITT): diagnostic and therapeutic recommendations for a new syndrome
M Franchini, GM Liumbruno… - European Journal of …, 2021 - Wiley Online Library
Very rare cases of thrombosis associated with thrombocytopenia have occurred following
the vaccination with AstraZeneca COVID‐19 vaccine. The aim of this concise review is to …
the vaccination with AstraZeneca COVID‐19 vaccine. The aim of this concise review is to …
Recommendations for the clinical and laboratory diagnosis of VITT against COVID‐19: communication from the ISTH SSC Subcommittee on Platelet Immunology
Vaccine administration is under way worldwide to combat the current COVID‐19 pandemic.
The newly developed vaccines are highly effective with minimal adverse effects. Recently …
The newly developed vaccines are highly effective with minimal adverse effects. Recently …
Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein
A Greinacher, K Selleng, J Mayerle… - Blood, The Journal …, 2021 - ashpublications.org
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe adverse effect of
ChAdOx1 nCoV-19 COVID-19 vaccine (Vaxzevria) and Janssen Ad26. COV2. S COVID-19 …
ChAdOx1 nCoV-19 COVID-19 vaccine (Vaxzevria) and Janssen Ad26. COV2. S COVID-19 …
Understanding long COVID; mitochondrial health and adaptation—old pathways, new problems
Many people infected with the SARS-CoV-2 suffer long-term symptoms, such as “brain fog”,
fatigue and clotting problems. Explanations for “long COVID” include immune imbalance …
fatigue and clotting problems. Explanations for “long COVID” include immune imbalance …
Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets
A subset of patients with coronavirus disease 2019 (COVID-19) become critically ill,
suffering from severe respiratory problems and also increased rates of thrombosis. The …
suffering from severe respiratory problems and also increased rates of thrombosis. The …